In this study, we performed a broad-spectrum analysis on data from The Cancer Genome Atlas (TCGA) and Genotype Tissue Expression (GTEx) consortia and in vitro drug sensitivity data from Genomics of Drug Sensitivity in Cancer (GDSC) and The Cancer Therapeutics Response Portal (CTRP) public projects to investigate the expression of BUB1 in different cancers and its role in influencing cancer response to various therapeutic strategies, with the goal to uncover BUB1 potential as biomarker in cancer. This evidence concerns the gene BUB1 and cancer.